Evidence map›Paper›PMID 38367882›Full record

ArticleNeurobiology of disease2024

TDP-43-M323K causes abnormal brain development and progressive cognitive and motor deficits associated with mislocalised and increased levels of TDP-43.

Juan M Godoy-Corchuelo, Zeinab Ali, Jose M Brito Armas, Aurea B Martins-Bach, Irene García-Toledo, Luis C Fernández-Beltrán, Juan I López-Carbonero, Pablo Bascuñana, Shoshana Spring, Irene Jimenez-Coca and 11 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Neurobiology of disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Challenges of modelling TDP-43 pathology in mice.Mammalian genome : official journal of the International Mammalian Genome Society · 2025
    Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 10 institutions in 4 countries.

Juan M Godoy-CorchueloNeurological Disorders Group, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdiSSC), Madrid 28040, Spain.
Zeinab AliNeurological Disorders Group, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdiSSC), Madrid 28040, Spain; MRC Harwell Institute, Oxfordshire, UK.
Jose M Brito ArmasUnidad de Investigación, Hospital Universitario de Canarias, ITB-ULL and CIBERNED, La Laguna, Spain.
Aurea B Martins-BachWellcome Centre for Integrative Neuroimaging, University of Oxford, Oxford, UK.
Irene García-ToledoNeurological Disorders Group, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdiSSC), Madrid 28040, Spain.
Luis C Fernández-BeltránNeurological Disorders Group, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdiSSC), Madrid 28040, Spain; Department of Medicine, Universidad Complutense de Madrid, Madrid, Spain.
Juan I López-CarboneroNeurological Disorders Group, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdiSSC), Madrid 28040, Spain.
Pablo BascuñanaBrain Mapping Group, Hospital Clínico San Carlos, IdISSC, Madrid, Spain.
Shoshana SpringMouse Imaging Centre, The Hospital for Sick Children, Toronto, ON, Canada.
Irene Jimenez-CocaNeurological Disorders Group, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdiSSC), Madrid 28040, Spain.
Ramón A Muñoz de Bustillo AlfaroUnidad de Investigación, Hospital Universitario de Canarias, ITB-ULL and CIBERNED, La Laguna, Spain.
Maria J Sánchez-BarrenaDepartment of Crystallography and Structural Biology, Institute of Physical Chemistry "Blas Cabrera", CSIC, Madrid, Spain.
Remya R NairMRC Harwell Institute, Oxfordshire, UK; Nucleic Acid Therapy Accelerator (NATA), Harwell Campus, Oxfordshire, UK.
Brian J NiemanMouse Imaging Centre, The Hospital for Sick Children, Toronto, ON, Canada.
Jason P LerchWellcome Centre for Integrative Neuroimaging, University of Oxford, Oxford, UK.
Karla L MillerWellcome Centre for Integrative Neuroimaging, University of Oxford, Oxford, UK.
Hande P OzdinlerDepartment of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Elizabeth M C FisherDepartment of Neuromuscular Diseases, and UCL Queen Square Motor Neuron Disease Centre, UCL, Institute of Neurology, London, UK.
Thomas J CunninghamMRC Harwell Institute, Oxfordshire, UK; MRC Prion Unit at UCL, UCL Institute of Prion Diseases, London, UK.
Abraham Acevedo-ArozenaUnidad de Investigación, Hospital Universitario de Canarias, ITB-ULL and CIBERNED, La Laguna, Spain. Electronic address: aacevedo@ull.edu.es.
Silvia CorrochanoNeurological Disorders Group, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdiSSC), Madrid 28040, Spain; MRC Harwell Institute, Oxfordshire, UK. Electronic address: silvia.corrochano@salud.madrid.org.
Instituto de Investigación Sanitaria del Hospital Clínico San Carlos · ESWellcome Centre for Integrative Neuroimaging · GBCentro de Investigación Biomédica en Red · ESHospital for Sick Children · CAMary Lyon Centre at MRC Harwell · GBHospital Universitario de Canarias · ESNational Hospital for Neurology and Neurosurgery · GBNorthwestern University · USUniversidad Complutense de Madrid · ESUniversity College London · GB

Funding

Medical Research Council MC_EX_MR/N501931/1
6 · The paper itself

Abstract

TDP-43 pathology is found in several neurodegenerative disorders, collectively referred to as "TDP-43 proteinopathies". Aggregates of TDP-43 are present in the brains and spinal cords of >97% of amyotrophic lateral sclerosis (ALS), and in brains of ∼50% of frontotemporal dementia (FTD) patients. While mutations in the TDP-43 gene (TARDBP) are usually associated with ALS, many clinical reports have linked these mutations to cognitive impairments and/or FTD, but also to other neurodegenerative disorders including Parkinsonism (PD) or progressive supranuclear palsy (PSP). TDP-43 is a ubiquitously expressed, highly conserved RNA-binding protein that is involved in many cellular processes, mainly RNA metabolism. To investigate systemic pathological mechanisms in TDP-43 proteinopathies, aiming to capture the pleiotropic effects of TDP-43 mutations, we have further characterised a mouse model carrying a point mutation (M323K) within the endogenous Tardbp gene. Homozygous mutant mice developed cognitive and behavioural deficits as early as 3 months of age. This was coupled with significant brain structural abnormalities, mainly in the cortex, hippocampus, and white matter fibres, together with progressive cortical interneuron degeneration and neuroinflammation. At the motor level, progressive phenotypes appeared around 6 months of age. Thus, cognitive phenotypes appeared to be of a developmental origin with a mild associated progressive neurodegeneration, while the motor and neuromuscular phenotypes seemed neurodegenerative, underlined by a progressive loss of upper and lower motor neurons as well as distal denervation. This is accompanied by progressive elevated TDP-43 protein and mRNA levels in cortex and spinal cord of homozygous mutant mice from 3 months of age, together with increased cytoplasmic TDP-43 mislocalisation in cortex, hippocampus, hypothalamus, and spinal cord at 12 months of age. In conclusion, we find that Tardbp M323K homozygous mutant mice model many aspects of human TDP-43 proteinopathies, evidencing a dual role for TDP-43 in brain morphogenesis as well as in the maintenance of the motor system, making them an ideal in vivo model system to study the complex biology of TDP-43.

Indexed as

Amyotrophic Lateral SclerosisFrontotemporal DementiaTDP-43 ProteinopathiesAnimalsBrainChild, PreschoolCognitionDNA-Binding ProteinsHumansMiceDNA-Binding ProteinsTardbp protein, mouseALS-FTDCognitive alterationsDevelopmentMotor disturbancesTDP-43TDP-43 Proteinopathies

Identifiers

PMID38367882
PMCPMC10988218
OpenAlexW4391848726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.